Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amneal PharmaceuticalsAMRX -1.96%56 Debt-to-EBITDA is 3.81 as of Mar. 2026, which is 47% below its 10-year median of 7.17. GuruFocus rates AMRX with a GF Score™ of 56/100 and a GF Value™ of $7.59 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Amneal Pharmaceuticals ranks worse than 77.97% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Amneal Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
AMRX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 4.31 Med: 7.17 Max: 34.39
Current: 4.31
During the past 10 years, the highest Debt-to-EBITDA Ratio of Amneal Pharmaceuticals was 34.39. The lowest was 4.31. And the median was 7.17.
AMRX's Debt-to-EBITDA is ranked worse than 77.97% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs AMRX: 4.31
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Amneal Pharmaceuticals Debt-to-EBITDA Related Terms
Amneal Pharmaceuticals Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Amneal Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMRX vs INDV, KNSA, LQDA: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Amneal Pharmaceuticals (AMRX) has a Debt-to-EBITDA of 3.81 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Amneal Pharmaceuticals. This is 47% below median its historical median of 7.17. Over the past decade, Amneal Pharmaceuticals' Debt-to-EBITDA has ranged from 4.31 to 34.39. According to the industry distribution chart, Amneal Pharmaceuticals ranks #538 out of 690 companies in the Drug Manufacturers industry, placing it in the top 78%.
Is Amneal Pharmaceuticals' Debt-to-EBITDA too high?
Amneal Pharmaceuticals' current Debt-to-EBITDA of 3.81 is 47% below median its 10-year median of 7.17. Over the past 10 years, this metric has ranged from a low of 4.31 to a high of 34.39. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Amneal Pharmaceuticals' value of 3.81 is 128.1% above this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #538 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amneal Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Debt-to-EBITDA compare to INDV and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #538 out of 690 companies for Debt-to-EBITDA. This places Amneal Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. Amneal Pharmaceuticals' value of 3.81 is 128.1% above this benchmark. Historically, Amneal Pharmaceuticals' own Debt-to-EBITDA has ranged from 4.31 to 34.39 over the past decade. While the company's 10-year median is 7.17 vs. the industry median of 1.67, Amneal Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current Debt-to-EBITDA of 3.81 is 128.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Amneal Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current Debt-to-EBITDA is 3.81, which is 47% below median its own 10-year median of 7.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.59, compared to a current price of $17.50 — trading 130.6% above its estimated fair value. The current Debt-to-EBITDA is 3.81, which is 47% below median its 10-year median of 7.17 and 128.1% above the Drug Manufacturers industry median of 1.67. Amneal Pharmaceuticals' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Debt-to-EBITDA is 3.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $17.50 is trading 130.6% above its estimated GF Value™ of $7.59.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
Debt-to-EBITDA: 3.81 (47% below median its 10-year median of 7.17)
GF Value™: $7.59 vs. price of $17.50 (130.6% above fair value)
Industry Position: 128.1% above the Drug Manufacturers median (#538 of 690)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
56GF Score
Get the complete analysis for AMRX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 
